Literature DB >> 25186487

[Successful eculizumab treatment for multiple coronary thrombosis complicated in paroxysmal nocturnal hemoglobinuria].

Ayuko Taniguchi1, Takayuki Ikezoe, Asako Takeuchi, Kazuto Togitani, Mitsuhiro Yoshimoto, Katsutoshi Tanioka, Hiroaki Kitaoka, Akihito Yokoyama.   

Abstract

We herein report a rare case of paroxysmal nocturnal hemoglobinuria (PNH) who repeatedly developed coronary arterial thromboembolism. Anticoagulant therapies including heparin, aspirin as an antiplatelet agent and even drug-eluting stent placement in the coronary artery failed to prevent the recurrence of ischemic heart disease. Of note, initiating the administration of a humanized anti-C5 antibody, eculizumab, achieved prompt thrombolysis and maintenance treatment with eculizumab prevented the recurrence of thromboembolic disease in this patient. Taking these observations together, we suggest that the use of eculizumab be considered for treatment or prevention of arterial thrombosis complicated by PNH, although arterial thrombosis is an extremely rare event in the Japanese population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25186487

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

1.  Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report.

Authors:  Anne Quinquenel; Quentin Maestraggi; Carinne Lecoq-Lafon; Peffault de Latour Régis; Alain Delmer; Amélie Servettaz
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.